Scalper1 News
Large-cap drugmakers Valeant Pharmaceuticals, Eli Lilly and Bristol-Myers Squibb all beat analysts’ Q2 estimates, but their stocks went in different directions, as their guidance was more mixed. Valeant (VRX) rose more than 6% after it said total revenue rose 34% to $2.73 billion, easily topping consensus views for $2.54 billion. The company’s organic growth, not including acquisitions, was 19% during the quarter. U.S. growth owed to Valeant’s Scalper1 News
Scalper1 News